Keros Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Keros Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q2 2024.
  • Keros Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $8.79M, a 24.8% increase year-over-year.
  • Keros Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $32.9M, a 48% increase year-over-year.
  • Keros Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $28.8M, a 54% increase from 2022.
  • Keros Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18.7M, a 59.4% increase from 2021.
  • Keros Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $11.7M, a 186% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $32.9M $8.79M +$1.74M +24.8% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $31.1M $8.07M +$2.38M +41.9% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $28.8M $7.32M +$2.58M +54.3% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $26.2M $8.71M +$3.96M +83.2% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $22.2M $7.04M +$2.25M +46.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $20M $5.69M +$1.3M +29.6% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $18.7M $4.75M +$1.45M +44% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 $17.2M $4.75M +$1.67M +54.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $15.6M $4.79M +$1.95M +68.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $13.6M $4.39M +$1.89M +75.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $11.7M $3.3M +$1.77M +116% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 $9.95M $3.08M +$1.66M +117% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $8.29M $2.85M +$1.71M +150% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $6.58M $2.49M +$2.48M +20683% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $4.1M $1.52M +$1.5M +8356% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-09
Q3 2020 $2.59M $1.42M +$1.41M +8276% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $1.19M $1.14M +$1.13M +8662% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $60K $12K +$1K +9.09% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $59K $18K Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $17K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $13K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-13
Q1 2019 $11K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-22
* An asterisk sign (*) next to the value indicates that the value is likely invalid.